171 related articles for article (PubMed ID: 38566133)
21. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
23. Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating Snail expression.
Dong Y; Sun X; Zhang K; He X; Zhang Q; Song H; Xu M; Lu H; Ren R
Bioengineered; 2021 Dec; 12(2):12967-12979. PubMed ID: 34939898
[TBL] [Abstract][Full Text] [Related]
24. Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
Sun B; Zhong FJ; Xu C; Li YM; Zhao YR; Cao MM; Yang LY
Cell Death Dis; 2021 Sep; 12(9):849. PubMed ID: 34521817
[TBL] [Abstract][Full Text] [Related]
25. CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.
Li D; Zhang Y; Zhang H; Zhan C; Li X; Ba T; Qiu Z; E F; Lv G; Zou C; Wang C; Si L; Zou C; Li Q; Gao X
J Exp Clin Cancer Res; 2018 Mar; 37(1):46. PubMed ID: 29506532
[TBL] [Abstract][Full Text] [Related]
26. Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process.
Yau WL; Lam CS; Ng L; Chow AK; Chan ST; Chan JY; Wo JY; Ng KT; Man K; Poon RT; Pang RW
PLoS One; 2013; 8(3):e57882. PubMed ID: 23483935
[TBL] [Abstract][Full Text] [Related]
27. MiR-552 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression.
Qu W; Wen X; Su K; Gou W
J Cell Mol Med; 2019 Feb; 23(2):1541-1552. PubMed ID: 30597727
[TBL] [Abstract][Full Text] [Related]
28. CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging.
Li Y; Chen G; Yan Y; Fan Q
Eur J Pharmacol; 2019 Oct; 860():172589. PubMed ID: 31401158
[TBL] [Abstract][Full Text] [Related]
29. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
30. Transcription factor specificity protein 1-mediated Serine/threonine kinase 39 upregulation promotes the proliferation, migration, invasion and epithelial-mesenchymal transition of hepatocellular carcinoma cells by activating the transforming growth factor-β1 /Smad2/3 pathway.
Wang J; Fan Z; Li J; Yang J; Liu X; Cheng J
Bioengineered; 2021 Dec; 12(1):3566-3577. PubMed ID: 34281492
[TBL] [Abstract][Full Text] [Related]
31. CAPZA1 modulates EMT by regulating actin cytoskeleton remodelling in hepatocellular carcinoma.
Huang D; Cao L; Zheng S
J Exp Clin Cancer Res; 2017 Jan; 36(1):13. PubMed ID: 28093067
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis.
You H; Yuan D; Bi Y; Zhang N; Li Q; Tu T; Wei X; Lian Q; Yu T; Kong D; Yang X; Liu X; Liu X; Kong F; Zheng K; Tang R
Cell Commun Signal; 2021 Mar; 19(1):33. PubMed ID: 33722250
[TBL] [Abstract][Full Text] [Related]
33. LncSNHG3 promotes hepatocellular carcinoma epithelial mesenchymal transition progression through the miR-152-3p/JAK1 pathway.
Li H; Wu Y; Wang R; Guo J; Yu Q; Zhang L; Zhao H; Yang H
Genes Genomics; 2022 Jan; 44(1):133-144. PubMed ID: 34778942
[TBL] [Abstract][Full Text] [Related]
34. CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling.
Liu Z; Chen M; Xie LK; Liu T; Zou ZW; Li Y; Chen P; Peng X; Ma C; Zhang WJ; Li PD
Aging (Albany NY); 2018 Oct; 10(10):2570-2584. PubMed ID: 30312171
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
[TBL] [Abstract][Full Text] [Related]
36. HSP4 triggers epithelial-mesenchymal transition and promotes motility capacities of hepatocellular carcinoma cells via activating AKT.
Ma P; Tang WG; Hu JW; Hao Y; Xiong LK; Wang MM; Liu H; Bo WH; Yu KH
Liver Int; 2020 May; 40(5):1211-1223. PubMed ID: 32077551
[TBL] [Abstract][Full Text] [Related]
37. ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma.
Huang W; Yu D; Wang M; Han Y; Lin J; Wei D; Cai J; Li B; Chen P; Zhang X
Cell Prolif; 2020 Jul; 53(7):e12836. PubMed ID: 32537856
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-148a Inhibits Hepatocellular Carcinoma Cell Growth via Epithelial-to-Mesenchymal Transition and PI3K/AKT Signaling Pathways by Targeting Death Receptor-5.
Zhang N; Zhou J; Zhou Y; Guan F
Appl Biochem Biotechnol; 2022 Jun; 194(6):2731-2746. PubMed ID: 35267120
[TBL] [Abstract][Full Text] [Related]
39. UNC119 promoted cell growth and migration by Wnt/β-catenin signal and TGF-β/EMT signal pathway in hepatocellular carcinoma.
Liu ZH; Zhang YF; Xu ZD; Z H L; Y F Z; Z D X
J BUON; 2018; 23(6):1717-1724. PubMed ID: 30610799
[TBL] [Abstract][Full Text] [Related]
40. Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma.
Zhang Y; Huang J; Li Q; Chen K; Liang Y; Zhan Z; Ye F; Ni W; Chen L; Ding Y
BMC Cancer; 2018 May; 18(1):539. PubMed ID: 29739365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
